47. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72(5): 1081–1091. 48. Ishikawa F, Yasukawa M, Lyons B et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005; 106(5): 1565–1573. 49. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engraftedwith mobilized human hemopoietic stem cells. J Immunol 2005; 174(10): 6477–6489. 50. Zhang X, Kim S, Hundal J et al. Breast cancer neoantigens can induce CD8 T cell responses and antitumor immunity. Cancer Immunol Res 2017; 5(7): 516–523. 51. Boegel S, Lower M, Bukur T et al. A catalog of HLA type, HLA expres- sion, and neo-epitope candidates in human cancer cell lines. Oncoimmunology 2014; 3(8): e954893. 52. Scholtalbers J, Boegel S, Bukur T et al. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and geneexpression. Genome Med 2015; 7(1): 118.